Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhimeng Biopharma Out-Licenses TLR8 Agonist, an HBV Therapy, to GSK

publication date: Feb 6, 2023

Shanghai Zhimeng Biopharma signed an agreement to out-license global rights for its TLR8 agonist to GlaxoSmithKline as an HBV treatment. Zhimeng is currently conducting a US Phase I trial of CB06, and GSK will acquire the rights – including development, manufacturing and commercialization -- if the candidate posts successful results. CB06 is a potential candidate for combination with GSK’s bepirovirsen, an antisense oligonucleotide that targets all HBV messenger RNAs to decrease virus load. GSK hopes to offer a virtual cure for HBV. The financial details of the agreement were not disclosed. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here